StockNews.AI
CYTK
StockNews.AI
15 hrs

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

1. A class action lawsuit filed against Cytokinetics for misleading investors. 2. Allegations focus on false timelines for aficamten's NDA approval. 3. Investors during the class period are eligible to join the lawsuit. 4. Failure to submit REMS could delay regulatory processes. 5. Class period spans from December 27, 2023, to May 6, 2025.

3m saved
Insight
Article

FAQ

Why Bearish?

The class action lawsuit suggests significant investor distrust, negatively affecting stock value, similar instances have previously led to drops in stock prices for affected companies.

How important is it?

The lawsuit stems from critical information about product approvals, crucial for investor confidence and stock viability.

Why Short Term?

Lawsuits can lead to immediate declines in stock price, typically within weeks to months as developments unfold.

Related Companies

PTCTNVAX
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. The Complaint specifically alleges that Defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process. Investors who purchased or otherwise acquired shares of Cytokinetics should contact the Firm prior to the November 17, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com. Please visit our website at http://www.gme-law.com for more information about the firm.

Related News